Companies agree up to $570m deal for C difficile drug
Drug Discovery World
FEBRUARY 27, 2023
Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence. Patients who have taken NTCD-M3 were found to be protected from toxic strains of CDI.
Let's personalize your content